Qiagen (QGEN) Rating Reiterated by Barclays

Barclays reissued their buy rating on shares of Qiagen (NYSE:QGEN) in a research report sent to investors on Thursday, September 6th. They currently have a $43.00 price target on the stock.

Other research analysts have also issued research reports about the company. Commerzbank reaffirmed a buy rating on shares of Qiagen in a research report on Tuesday, August 7th. DZ Bank reaffirmed a neutral rating on shares of Qiagen in a research report on Tuesday, June 5th. Citigroup upped their price target on Qiagen from $35.00 to $38.00 and gave the company a neutral rating in a research report on Thursday, August 2nd. Goldman Sachs Group reissued a buy rating on shares of Qiagen in a research report on Wednesday, May 16th. Finally, ValuEngine raised Qiagen from a hold rating to a buy rating in a research report on Monday, July 2nd. Five investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Qiagen has an average rating of Buy and an average target price of $39.60.

Shares of NYSE QGEN traded down $0.72 during midday trading on Thursday, reaching $37.51. The company had a trading volume of 891,878 shares, compared to its average volume of 741,423. Qiagen has a one year low of $30.20 and a one year high of $39.45. The company has a current ratio of 1.79, a quick ratio of 1.62 and a debt-to-equity ratio of 0.53. The firm has a market cap of $8.69 billion, a PE ratio of 28.42, a price-to-earnings-growth ratio of 2.35 and a beta of 1.11.

Qiagen (NYSE:QGEN) last released its earnings results on Tuesday, July 31st. The company reported $0.33 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.01. The company had revenue of $377.20 million during the quarter, compared to analyst estimates of $376.89 million. Qiagen had a return on equity of 12.22% and a net margin of 5.26%. equities research analysts forecast that Qiagen will post 1.33 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

See Also: What Factors Can Affect Return on Equity?

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply